Nkarta, Inc. (NKTX) stock
Close on Nov 12, 2026Market cap $90.61MP/E –Yield 0.00%
Nkarta, Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$102.31M. At the latest close the market valued the company at $90.61M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $90.61M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.42
- Dividend yield
- 0.00%
- Free cash flow yield
- -112.91%
Fundamentals
- Revenue
- $0
- Net income
- -$128.94M
- EPS, diluted
- -$1.73
- Free cash flow
- -$102.31M
- Book value per share
- $2.89
- Diluted shares
- 75M
Trading
- Next earnings
- Mar 24, 2027 (estimated, during market hours)
- Previous close
- $1.48
- Open
- $1.43
- Day's range
- $1.26 – $1.43
- Volume
- 1,026,927
- Average volume (20 days)
- 1,737,783
- Index membership
- Russell 2000 (since Sep 2020), Russell 3000 (since Nov 2020)
- Beta (5 years)
- 1.16
- 52-week range
- $1.13 – $3.72
- RSI (14 days)
- 31.4
- Volatility (1 year)
- 78.1%
- Relative volume
- 1.16×
- WACC
- 10.8%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NKTX | S&P 500 | Difference | NKTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -41.7% | -2.7% | −39.0 pts | ||
| 3 months | -47.1% | -1.7% | −45.3 pts | ||
| Year to date | -31.6% | +11.9% | −43.5 pts | ||
| 1 year | -35.5% | +12.0% | −47.4 pts | ||
| 3 years | -37.7% | +78.2% | −115.9 pts | -14.6% | +21.2% |
| 5 years | -93.5% | +73.2% | −166.8 pts | -42.2% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nkarta filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Results
About Nkarta
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical organization focused on creating allogeneic, off-the-shelf engineered natural killer cell therapies. Its primary pipeline candidate, NKX019, is an engineered chimeric antigen receptor natural killer cell product designed to target the CD19 antigen. This lead candidate aims to treat various autoimmune conditions, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. It previously evaluated product candidates in oncology indications before redirecting its primary resources toward autoimmune diseases.
Company profile, executives and historyNkarta stock: common questions
What is Nkarta's stock price?
NKTX closed at $1.26 on Nov 12, 2026, down 14.53% on the day. Over the past 52 weeks it traded between $1.13 and $3.72.
What is Nkarta's market cap?
Nkarta was worth $90.61M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NKTX's P/E ratio?
Nkarta lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.73), so it has no meaningful P/E ratio.
How much revenue does Nkarta make?
Nkarta reported revenue of $0 for fiscal 2025.
Does Nkarta pay a dividend?
No. Nkarta has not paid a cash dividend over the last twelve months.
When does Nkarta report earnings next?
Nkarta is expected to report Q4 FY2026 results on Mar 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has NKTX stock performed over the past year?
Including dividends, NKTX returned -35.5% over the past year, against +12.0% for the S&P 500.
How many NKTX shares are sold short?
4M shares were sold short at the latest FINRA report, 8.35% of the float, or 2.9 days of average trading volume.
Who are Nkarta's competitors?
Companies most similar to Nkarta by business, industry and size include NKTR, GRI, VERA, ACET, RNAC.
See a number that looks wrong?